Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H. Hughes R, et al. Among authors: pedotti r. Mult Scler Relat Disord. 2021 Apr;49:102725. doi: 10.1016/j.msard.2020.102725. Epub 2020 Dec 30. Mult Scler Relat Disord. 2021. PMID: 33482590 Free PMC article.
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel.
Weberpals J, Roumpanis S, Barer Y, Ehrlich S, Jessop N, Pedotti R, Vaknin-Dembinsky A, Brill L, Chodick G, Rouzic EM. Weberpals J, et al. Among authors: pedotti r. Mult Scler Relat Disord. 2022 Dec;68:104153. doi: 10.1016/j.msard.2022.104153. Epub 2022 Aug 29. Mult Scler Relat Disord. 2022. PMID: 36081277 Free PMC article.
Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
Guerrera G, Mandelli A, Finardi A, Orrico M, D'Orso S, Picozza M, Noviello M, Beretta V, Bonetti B, Calabrese M, Marastoni D, De Rossi N, Capra R, Salvetti M, Buscarinu MC, Inglese M, Uccelli A, Moiola L, Raposo C, Muros-Le Rouzic E, Pedotti R, Filippi M, Bonini C, Battistini L, Borsellino G, Furlan R. Guerrera G, et al. Among authors: pedotti r. Mult Scler. 2022 Oct;28(12):1937-1943. doi: 10.1177/13524585221102158. Epub 2022 Jun 20. Mult Scler. 2022. PMID: 35723265
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: pedotti r. Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1. Ann Neurol. 2022. PMID: 35289960 Free PMC article.
54 results